(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-[5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophen-2-yl]-methanone | 947540-60-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: (1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-[5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophen-2-yl]-methanone
• 英文别名: 1,4-Dioxa-8-azaspiro[4.5]decan-8-yl-[5-[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]thiophen-2-yl]methanone
• CAS: 947540-60-5
• 化学式: C₁₇H₁₈F₃N₃O₃S
• 分子量: 401.409
• InChiKey: HMNYYLSYKXVFHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  84.8
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• Therapeutic Compounds
  申请人：Zhou Xianbo

  公开号：US20070203154A1

  公开（公告）日：2007-08-30

  The invention provides a compound of formula I: wherein R 1 -R 6 , X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of MAO-B enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.

  这项发明提供了一个式I的化合物： 其中R1-R6，X，Y和B具有本文所述的任何值，以及这些化合物的盐、包含这些化合物的组合物，以及包括给予这些化合物的治疗方法。这些化合物是MAO-B酶功能的抑制剂，对于改善认知功能和治疗动物的精神障碍是有用的。
• THERAPEUTIC COMPOUNDS
  申请人：Helicon Therapeutics, Inc.

  公开号：EP1989185B1

  公开（公告）日：2013-05-22
• PYRAZOLE COMPOUNDS AND USES THEREOF
  申请人：Zhou Xianbo

  公开号：US20110160248A1

  公开（公告）日：2011-06-30

  The invention provides a compound of formula I: wherein R 1 -R 6 , X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of MAO-B enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.
• MAO-B INHIBITORS AND REHABILITATION
  申请人：DART NEUROSCIENCE (CAYMAN) LTD.

  公开号：US20170273968A1

  公开（公告）日：2017-09-28

  Methods of rehabilitation of neurological disorders, including neurological deficits associated with neurotraumas, such as stroke and traumatic brain injury, and with muscle disorders, that includes administering to a subject a MAO-B inhibitor.
• US7919626B2
  申请人：——

  公开号：US7919626B2

  公开（公告）日：2011-04-05